Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, inhibits the
replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at …

A recent outbreak of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus
designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in …

The coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality
among infected individuals across the world. High transmissibility rate of the causative virus …

Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus …

An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs
have been approved for the treatment of COVID‐2019. In addition to the recommended …

Favipiravir is a novel broad-spectrum antiviral drug against RNA viruses that has been
approved for the treatment of seasonal and pandemic influenza. The use of favipiravir is a …

Objective To assess the efficacy and safety of favipiravir in adults with mild-to-moderate
coronavirus disease 2019 (COVID-19). Methods In this randomized, open-label, parallel …

Abstract The coronavirus disease-2019 (COVID-19) outbreak all over the world has led the
researchers to strive to develop drugs or vaccines to prevent or halt the progression of this …

Background The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an
enzyme RNA dependent RNA polymerase for its replication. Favipiravir (FVP) triphosphate …

Background Favipiravir, an oral, RNA-dependent RNA polymerase inhibitor, has in vitro
activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite …